Zoetis (ZTS) Cash & Current Investments (2012 - 2026)
Zoetis' (ZTS) quarterly Cash & Current Investments came in at $1.9 billion in Q1 2026, up 12.78% year-on-year from $1.7 billion in Q1 2025, and down 20.78% on a QoQ basis from $2.4 billion in Q4 2025.
Zoetis (ZTS) Cash & Current Investments (2012 - 2026) Analysis & Trends
Zoetis (ZTS) has 15 years of Cash & Current Investments data on file, last reported at $1.9 billion in Q1 2026.
- On a quarterly basis, Cash & Current Investments rose 12.78% year-over-year to $1.9 billion in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 12.78% increase from a year earlier, with the FY2025 full-year figure at $2.4 billion, up 23.3% from the prior year.
- Cash & Current Investments for Q1 2026 stood at $1.9 billion, down from $2.4 billion in the prior quarter.
- Over the last five years, Cash & Current Investments for ZTS reached as high as $3.6 billion in Q4 2022 and fell as low as $1.4 billion in Q2 2025.
- Historically, Cash & Current Investments has averaged $2.1 billion across 5 years, with a median of $2.0 billion in 2024.
- Across the five-year window, Cash & Current Investments tumbled 43.0% in 2023 and climbed 23.3% in 2025, its largest moves.
- Year by year, Cash & Current Investments stood at $3.6 billion in 2022, then tumbled by 43.0% to $2.0 billion in 2023, then slipped by 2.65% to $2.0 billion in 2024, then increased by 23.3% to $2.4 billion in 2025, then fell by 20.78% to $1.9 billion in 2026.
- Per Business Quant data, the three most recent Cash & Current Investments figures were $1.9 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.1 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | 1.86 Bn |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 3.74 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 1.94 Bn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 4.06 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 2.15 Bn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 1.80 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 1.32 Bn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 428.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 153.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.94 Bn |
| Dec 31, 2025 | 2.45 Bn |
| Sep 30, 2025 | 2.08 Bn |
| Jun 30, 2025 | 1.44 Bn |
| Mar 31, 2025 | 1.72 Bn |
| Dec 31, 2024 | 1.99 Bn |
| Sep 30, 2024 | 1.71 Bn |
| Jun 30, 2024 | 1.57 Bn |
| Mar 31, 2024 | 1.98 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Sep 30, 2023 | 1.75 Bn |
| Jun 30, 2023 | 1.72 Bn |
| Mar 31, 2023 | 2.11 Bn |
| Dec 31, 2022 | 3.58 Bn |
| Sep 30, 2022 | 2.51 Bn |
| Jun 30, 2022 | 2.65 Bn |
| Mar 31, 2022 | 3.14 Bn |
| Dec 31, 2021 | 3.49 Bn |
| Sep 30, 2021 | 3.27 Bn |
| Jun 30, 2021 | 3.66 Bn |